Butamoxane

This classification denotes an adrenergic antagonist with the molecular formula C13H19NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7725983GSD, chemically known as 1,4-benzodioxan-2-methylamine, n-butyl- but generally known as butamoxane, which bears US NIH Compound Identifier 20504. European Medicines Agency schedules Butamoxane in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06002MIG. The term BUTAMOXANE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 19 1975, List 5). BUTAMOXANE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule butamoxane under HS 29329985 and SITC 51569. As of Q4 2014, BUTAMOXANE remains the US FDA Preferred Term for this commodity. Butamoxane bears US NLM identifiers UMLS ID C0606819 and NCI Concept Code C74104. SMILES: O1C(CNCCCC)COC2C1CCCC2.